Franklin Covey offers visible and predictable growth in the $55B management training market, so don't sell the company's stock despite its surging price, says Michael Balkin, portfolio manager for the William Blair Small Cap Growth Fund. Balkin says Ligand Pharmaceuticals shares are also a smart buy because the biotech has 7 royalty producing drugs and another 90 in the pipeline. Finally, Balkin is bullish on CoStar Group's stock, saying the company is the Bloomberg of the real estate space. While the stock trades at a high multiple to sales and earnings, Balkin says it has highly visible recurring revenue and a long runway for growth.

More from Video

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

This Could Be the Summer of Hard Seltzer

This Could Be the Summer of Hard Seltzer